{"favorite_id": 2142, "calc_type": "", "dosing": false, "full_title_en": "Manchester Score for Prognosis in Small Cell Lung Cancer", "short_title_en": "Manchester Score for Lung Cancer", "medium_description_en": "Predicts 2 year survival of small cell lung cancer.", "short_description_en": "2 year survival of small cell lung CA.", "before_use": "", "instructions_en": "", "purpose_en": ["Prognosis", "Treatment"], "disease_en": ["Cancer", "Chemotherapy", "Lung Cancer"], "specialty_en": ["Hematology and Oncology", "Palliative Care/Hospice", "Pulmonology"], "chief_complaint_en": ["Shortness of Breath", "Weight Loss/Gain"], "system_en": ["Oncologic"], "search_abbreviation_en": ["ca", "small cell lung cancer", "survival", "prognosis"], "slug": "manchester-score-prognosis-small-cell-lung-cancer", "seo": {"meta_description_en": "The Manchester Score for Prognosis in Small Cell Lung Cancer predicts 2 year survival of small cell lung cancer.", "keywords_en": "manchester score, manchester prognosis score, manchester px, manchester cancer score, manchester lung ca, lung cancer prognosis, lung ca prognosis score, small cell lung ca, small cell lung cancer, small cell cancer score"}, "content": {"how_to_use": {"use_case_en": "<p>It has been used to determine when to administer chemotherapy in the ICU to admitted lung cancer patients.(<a href='http://www.ncbi.nlm.nih.gov/pubmed/24102014' target='_blank'>Zarogoulidis 2013</a>)</p>", "pearls_pitfalls_en": "<p>The score distinguishes three prognostic groups with overall two-year survival rates of 16.2%, 2.5%, and 0%.</p>", "why_use_en": ""}, "next_steps": {"advice_en": "<p>The scoring system may help in the design of new treatment strategies and may assist in the comparison of different studies.</p>", "management_en": "", "critical_actions_en": ""}, "about": {"formula_en": "<p>Addition of assigned points. If Karnofsky Performance Scale &lt;60, item is assigned 1 point.</p>", "more_info_en": "<p>Original Study:</p> <ul> <li>407 patients with SCLC, seen between 1979 and 1985.</li> <li>All patients received short-term intensive regimens (cyclophosphamide, etoposide and methotrexate or ifosfamide and etoposide, both followed by thoracic irradiation if complete response was noted).</li> </ul> <div class='table-responsive'> <table class='table table-bordered table-hover'> <tbody> <tr> <th><strong>Manchester score</strong></th> <th><strong>Prognostic group</strong></th> <th><strong>Two year survival (%)</strong></th> </tr> <tr> <td>\u22641</td> <td>Good</td> <td>16.2</td> </tr> <tr> <td>2 - 3</td> <td>Medium</td> <td>2.5</td> </tr> <tr> <td>\u22654</td> <td>Poor</td> <td>0</td> </tr> </tbody> </table> </div>", "evidence_based_medicine_en": "", "references_list": {"Original/Primary Reference": [{"href": "https://www.ncbi.nlm.nih.gov/pubmed/3026969", "text": "Cerny, T; Blair V, Anderson H et al. Pretreatment prognostic factors and scoring system in 407 small-cell lung cancer patients. International Journal of Cancer. 1987, (2): 146\u2013149."}], "Other References": [{"href": "https://www.ncbi.nlm.nih.gov/pubmed/9261523", "text": "Maestu, I; Pastor M, G\u00f3mez-Codina J et al. (Jun 1997). Pretreatment prognostic factors for survival in small-cell lung cancer: a new prognostic index and validation of three known prognostic indices on 341 patients .Annals of Oncology 8 (6): 547\u2013553. doi:10.1023/A:1008212826956. PMID 9261523."}, {"href": "http://www.ncbi.nlm.nih.gov/pubmed/24102014", "text": "Zarogoulidis P, et al. Intensive care unit and lung cancer: when should we intubate? J Thorac Dis. 2013 Sep;5 Suppl 4:S407-12. doi: 10.3978/j.issn.2072-1439.2013.08.15."}], "Validation": [{"href": "https://www.ncbi.nlm.nih.gov/pubmed/9255270", "text": "Kawahara, Masaaki; Masahiro Fukuoka, Nagahiro Saijo et al. (1996). Prognostic factors and prognostic staging system for small cell lung cancer. Japanese Journal of Clinical Oncology (Oxford University Press) 27 (3): 158\u2013165. doi:10.1093/jjco/27.3.158. PMID 9255270. ISSN: 0368-2811."}], "Clinical Practice Guidelines": [], "Manufacturer Website": [], "Outcomes": []}}, "contributor": {"expert_name": []}, "creator": [{"name": "Dr. Thomas Cerny", "qa_en": "<p dir=\"ltr\"><strong>What pearls, pitfalls and/or tips do you have for users of the Manchester Score for Lung Cancer? Do you know of cases when it has been applied, interpreted, or used inappropriately?</strong></p>\n<p dir=\"ltr\">It&rsquo;s easy to use and the therapeutic options are pretty much the same as today. Only bicarbonate might not be used routinely, but it&rsquo;s easy and cheap. This might change in the near future with the advent of new treatment options, but I have not heard as to any pitfalls with the Manchester Score.</p>\n<p dir=\"ltr\"><strong>What recommendations do you have for doctors once they have applied the Manchester Score for Lung Cancer? Are there any adjustments or updates you would make to the score based on new data or practice changes?</strong></p>\n<p dir=\"ltr\">Not to my knowledge.</p>\n<p dir=\"ltr\"><strong>Why did you develop the Manchester Score for Lung Cancer? Was there a particular clinical experience or patient encounter that inspired you to create this tool for clinicians?</strong></p>\n<p dir=\"ltr\">35 years ago, more prognostic information was asked by patients and treating physicians for, i.e., shared decision making, and since there is a small chance of cure in SCLC, any prognostically validated information could help to make the best treatment choice in individual cases.</p>\n<p dir=\"ltr\"><strong>How do you use the Manchester Score for Lung Cancer in your own clinical practice? Can you give an example of a scenario in which you use it?</strong></p>\n<p><span id=\"docs-internal-guid-1b3bede6-7fff-0acb-44f3-eb2cb5234b1d\"></p>\n<p dir=\"ltr\">N/A - I am retired since a few years and no more treating patients.</p>", "approved": false, "creator_info": {"about_en": "<p>Thomas Cerny, MD, is the former chief of hematology and oncology at Kantonsspital St Gallen and also a professor of medical oncology at the University of Berne. He is president of the Swiss Cancer Foundation and Oncosuisse. Dr. Cerny researches multiple types of cancer including sarcoma and lung cancer.</p>", "photo_en": "https://cdn-web-img.mdcalc.com/people/dr-thomas-cerny.jpeg", "pubmedLink": "https://www.ncbi.nlm.nih.gov/pubmed/?term=Cerny+T%5BAuthor%5D"}}], "reviewer": {"expert_name": []}, "related_resources": {"mdcalc_rating": [], "guidelines": [], "teaching": [], "videos": [], "interests": [], "partner_contact": [], "sdm_tool": []}}, "input_schema": [{"type": "toggle", "label_en": "Serum LDH > upper limit of normal", "default": 0, "conditionality": "", "show_points": true, "tips_en": "", "optional": false, "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "name": "ldh"}, {"type": "toggle", "label_en": "Serum Na < 132 mmol/L", "default": 0, "conditionality": "", "show_points": true, "tips_en": "", "optional": false, "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "name": "na"}, {"type": "toggle", "label_en": "Serum alkaline phosphatase > 1.5x the upper limit of normal", "default": 0, "conditionality": "", "show_points": true, "tips_en": "", "optional": false, "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "name": "alkPhos"}, {"type": "toggle", "label_en": "Serum bicarbonate < 24", "default": 0, "conditionality": "", "show_points": true, "tips_en": "", "optional": false, "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "name": "bicarb"}, {"type": "toggle", "label_en": "Extensive stage disease", "default": 0, "conditionality": "", "show_points": true, "tips_en": "", "optional": false, "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "name": "stage"}, {"type": "radio", "label_en": "Karnofsky Performance Status", "default": 0, "conditionality": "", "show_points": false, "tips_en": "", "optional": false, "options": [{"label": "100 -- Normal. No complaints. No evidence of disease.", "value": 0}, {"label": "90 -- Able to carry on normal activity. Minor signs or symptoms of disease.", "value": 0}, {"label": "80 -- Normal activity with effort. Some signs or symptoms of disease.", "value": 0}, {"label": "70 -- Cares for self. Unable to carry on normal activity or to do active work.", "value": 0}, {"label": "60 -- Requires occasional assistance, but is able to care for most of his/her personal needs.", "value": 0}, {"label": "50 -- Requires considerable assistance and frequent medical care.", "value": 1}, {"label": "40 -- Disabled. Requires special care and assistance.", "value": 1}, {"label": "30 -- Severely disabled. Hospital admission is indicated although death not imminent.", "value": 1}, {"label": "20 -- Very sick. Hospital admission necessary. Active supportive treatment necessary.", "value": 1}, {"label": "10 -- Moribund. Fatal processes progressing rapidly.", "value": 1}], "name": "karnofsky"}], "md5": "", "related_calcs": [{"calcId": 10187, "short_title_en": "Pack Years Calculator", "slug": "pack-years-calculator"}, {"calcId": 10178, "short_title_en": "TNM Pancreatic CA Staging (8th Ed.)", "slug": "tnm-staging-pancreatic-cancer-8th-edition"}, {"calcId": 3314, "short_title_en": "TNM Pancreatic CA Staging", "slug": "tnm-staging-pancreatic-cancer"}]}